Abbott Laboratories (NYSE:ABT) Q2 2024 Earnings Conference Call July 18, 2024 9:00 AM ET
Company Participants
Robert Ford - Chief Executive Officer
Phil Boudreau - Executive Vice President, Finance, Chief Financial Officer
Mike Comilla - Vice President, Investor Relations
Conference Call Participants
Larry Biegelsen - Wells Fargo
Travis Sneed - Bank of America
Robbie Marcus - JP Morgan
Josh Jennings - TD Cowen
David Roman - Goldman Sachs
Danielle Antalffy - UBS
Vijay Kumar - Evercore ISI
Operator
Good morning and thank you for standing by. Welcome to Abbott’s second quarter 2024 earnings conference call.
All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star-one-one keys on your touchtone phone. This call is being recorded by Abbott.
With the exception of any participants’ questions asked during the question and answer session, the entire call including the question and answer session is material copyrighted by Abbott. It cannot be recorded or rebroadcast with Abbott’s express written permission.
I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
Mike Comilla
Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we’ll take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2024. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott’s operations are discussed in Item Ia, Risk Factors to our annual report on Form 10-K for the year ended December 31, 2023. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
On today’s conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott’s ongoing business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict future changes in foreign exchange rate, which could impact reported sales growth. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today.